Oura to acquire Counsel Health for $625 million, expanding into AI‑powered health services

The Finnish wearable company Oura disclosed on Tuesday its plan to purchase AI‑centric primary‑care startup Counsel Health for roughly $625 million, representing its largest step into the wider health‑services arena.

The deal follows a few weeks after Oura abandoned a slated IPO that might have generated as much as $2.2 billion, pointing to persistent volatility in the stock market. Redirecting capital toward this strategic buyout instead of a public float suggests Oura is counting on organic expansion and diversification to preserve its market value.

Founded in 2021, Counsel Health has developed a platform that combines AI‑driven triage, telehealth consultations, and EHR integration to provide scalable primary‑care. The system processes information from wearables, medical histories and live symptom reports, giving clinicians decision‑support utilities that speed up diagnosis and treatment routes.

Analysts view the transaction as a natural expansion of Oura’s data‑intensive ecosystem. The ring’s measurements of sleep, activity and readiness are already supplied to insurers and corporate wellness schemes; incorporating a direct‑care layer could let Oura convert those insights into revenue more directly, transforming raw biometrics into practical medical actions.

The purchase mirrors a wider pattern of consolidation among health‑tech companies as investors look for all‑in‑one offerings that merge monitoring, analytics and clinical services. AI‑powered primary care has drawn considerable venture funding lately, yet numerous startups find it difficult to reach the scale necessary to rival established health networks. Aligning with a recognized name such as Oura could provide Counsel Health with the distribution reach and brand trust needed to speed up uptake.

However, the merger will face challenges. Combining a consumer‑oriented hardware firm with a regulated medical‑service entity brings up concerns over data privacy, adherence to health‑care regulations, and cultural fit. Oura must steer through these issues while proving that the joint solution enhances outcomes and provides value to patients and insurers alike.

Going forward, the transaction could alter Oura’s long‑term fiscal plan. Should the merged company manage to produce steady income from care services, it might return to the public markets with a more compelling story than a solely hardware venture. At present, the $625 million acquisition underscores Oura’s ambition to shift from a specialized wellness tracker to a broader health‑technology platform.